Bellevue Asset Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Bellevue Asset Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-49	Closed	-$2K	–	598
2021 Q3	$2K	Hold	49	–	–	﹤0.01%	550
2021 Q2	$2K	Sell	49 -7	-13%	-$271	﹤0.01%	550
2021 Q1	$3K	Sell	56 -2	-3%	-$93	﹤0.01%	545
2020 Q4	$3K	Sell	58 -9	-13%	-$533	﹤0.01%	559
2020 Q3	$3K	Hold	67	–	–	﹤0.01%	513
2020 Q2	$4K	Hold	67	–	–	﹤0.01%	452
2020 Q1	$3K	Buy	67 +40	+148%	+$2.22K	﹤0.01%	476
2019 Q4	$2K	Buy	+27	New	+$1.28K	﹤0.01%	469

Other funds holding DCPH

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Asset Management's DCPH Position: Q4 2021 in Review

Bellevue Asset Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2021, closing a stake of 49 shares — an estimated $2K sold.

Bellevue Asset Management first reported a position in DCPH in Q4 2019 and held it in 8 quarters. The position peaked at $4K in Q2 2020. 140 funds tracked by Wall St. Rank hold DCPH as of Q4 2021.

Bellevue Asset Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Bellevue Asset Management sold 49 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $2K.
Bellevue Asset Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
Bellevue Asset Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q2 2020.
140 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Bellevue Asset Management's 13F filing for Q4 2021, filed 3 Feb 2022.